Reduction in migraine-associated burden after eptinezumab treatment in patients with chronic migraine

OBJECTIVE: To examine changes in the occurrence, severity, and symptoms of headache episodes in patients with chronic migraine following eptinezumab treatment. METHODS: PROMISE-2 was a double-blind, placebo-controlled, parallel-group trial that randomized adults with chronic migraine to eptinezumab...

Descripción completa

Detalles Bibliográficos
Autores principales: McAllister, Peter, Kudrow, David, Cady, Roger, Hirman, Joe, Ettrup, Anders
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9445399/
https://www.ncbi.nlm.nih.gov/pubmed/35332807
http://dx.doi.org/10.1177/03331024221089567

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9445399/
https://www.ncbi.nlm.nih.gov/pubmed/35332807
http://dx.doi.org/10.1177/03331024221089567

Ejemplares similares